IBI188
A Phase 1b Study Evaluating the Safety and Efficacy of IBI188 in Combination With Azacitidine in Subjects With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (MDS)
More Information
- Trial Status
- Not currently accepting
- Trial Phase
- Phase 1
- Enrollment
- 32 patients (estimated)
- Sponsors
- Innovent Biologics (Suzhou) Co. Ltd.
- Tags
- Monoclonal Antibody, CD47
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1370
- NCT Identifier
- NCT04511975
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.